MYBL2 and breast carcinoma: We performed experiments with cell lines representing various breast cancer subtypes to test our hypothesis that paclitaxel acts synergistically with doxorubicin via suppression of MELK, which in turn attenuates MYBL2 gene expression, known to be advantageous for chemotherapy response.